SCHEMBL17016029

SCHEMBL17016029

c1ccc(-c2ccc3c(c2)c2cc(-c4ccccc4)ccc2n3-c2cccc(-n3c4ccccc4c4ccc5c(-c6ccccc6)cn(-c6ccccc6)c5c43)c2)cc1

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.38
▸ ATM Q13315 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ TSPO P30536 3/20 0.34
▸ ESR1 P03372 1/20 0.34
▸ ESRRA P11474 1/20 0.34
▸ ESR2 Q92731 1/20 0.34
▸ DYRK1A Q13627 1/20 0.33
▸ PTGER1 P34995 1/20 0.32
▸ HTR6 P50406 1/20 0.32
▸ HTR7 P34969 1/20 0.32
▸ RXRA P19793 1/20 0.31
▸ RXRB P28702 1/20 0.31
▸ POLB P06746 1/20 0.31
▸ CTDSP1 Q9GZU7 1/20 0.31
▸ HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17016028 1.00 KDM4E (0.38) KDM4EATML3MBTL1TSPOESR1
SCHEMBL17016027 0.94 KDM4E (0.37) KDM4EATML3MBTL1TSPOESR1
SCHEMBL17016033 0.94 KDM4E (0.37) KDM4EATML3MBTL1TSPOESR1
SCHEMBL17016030 0.94 KDM4E (0.39) KDM4EATML3MBTL1ESR1ESRRA
SCHEMBL17016026 0.94 KDM4E (0.42) KDM4EATML3MBTL1TSPOESR1
SCHEMBL17016023 0.94 KDM4E (0.42) KDM4EATML3MBTL1TSPOESR1
SCHEMBL17016031 0.93 KDM4E (0.44) KDM4EATML3MBTL1ESR1ESRRA
SCHEMBL17016024 0.92 KDM4E (0.40) KDM4EATML3MBTL1TSPOESR1
SCHEMBL17015966 0.92 KDM4E (0.36) KDM4EATML3MBTL1ESR1ESRRA
SCHEMBL17015968 0.91 KDM4E (0.36) KDM4EATML3MBTL1ESR1ESRRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 — — US disclosed
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 — — US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 — — US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME INMT, IDO1, IDO2 KDM4E 1286/4885ATM 3623/4885L3MBTL1 533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback